Strategies for insulin initiation: Insights from the French LIGHT observational study

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 1, 2012, Pages 97-105

  Vergès, Bruno ^a   Brun, Jean Marcel ^a   Tawil, Camille ^b   Alexandre, Bertrand ^c   Kerlan, Véronique ^d  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b Boulevard Pereire ^*  (France)

^c NOVO NORDISK A S   (Denmark)

^d SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Basal analogue; Detemir; Glargine; Insulin initiation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; METFORMIN PLUS REPAGLINIDE; SULFONYLUREA;

ADULT; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR SYMPTOM; CHOLANGITIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FOLLOW UP; FRENCH GUIANA; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INTROSPECTION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; SIDE EFFECT; TELEPHONE; WEIGHT GAIN;

AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; LIFE STYLE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 84855408801     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1288     Document Type: Article

References (36)

1. Esposito K, Ciotola M, Maiorino MI, Giugliano D. Lifestyle approaches for type 2 diabetes and metabolic syndrome. Curr Atheroscler Rep 2008; 10: 523-528.
2. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
3. Funnel NN. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes 2007; 25: 36-38.
4. Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature review. J Diabetes Complicat 2006; 20: 402-408.
5. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987; 10: 617-621.
6. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl 3): S18-S24.
7. Arendt-Nielsen L, Egekvist H, Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res 2006; 23: 37-43.
8. Brunton SA, Davis SN, Renda SM. Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone 2006; 8(Suppl 2): S19-S26.
9. Peyrot M, Rubin RR, Lauritzin T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes Wishes and Needs (DAWN) Study. Diabet Med 2005; 22: 1379-1385.
10. International Diabetes Federation. Diabetes Atlas (4th edn). International Diabetes Federation: Brussels, Belgium, 2009.
11. Brez S, Rowan M, Malcolm J, et al. Transition from specialist to primary diabetes care: a qualitative study of perspectives of primary care physicians. BMC Fam Pract 2009; 10: 39.1-39.8.
12. Hovath K, Jeitler K, Berghold A, et al. Long-acting analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; 2: CD005613.
13. Bazzano LA, Lee LJ, Reynolds K, Jackson JA, Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab 2008; 25: 924-932.
14. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28: 1569-1581.
15. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9: 648-659.
16. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping mechanisms. Diabetes Obes Metab 2007; 9: 799-812.
17. Agence Française de Sécurité Sanitaire des Produits de Santé-Haute Autorité de Santé (AFSSAPS-HAS). Traitement médicamenteux du diabète de type 2 (actualisation). Recommendation de bonne practique. Diabetes Metab 2007; 33: 1S1-1S6.
18. Fortin C, Yale J-F, White M, Langlois MS. DICE: le contrôle du diabète de type 2, étude canadienne Octobre 2005. Diabète Québec. [12 May 2010].
19. Echantillon national témoin représentatif des personnes diabétiques (Entred) 2007-2010. [12 May 2010].
20. Robert J, Roudier C, Poutignat N, et al. for the ENTRED scientific committee 2007-2010. Health care of persons with type 2 diabetes in France in 2007 and trends compared to 2001. BEH Thematique 2009; 42-43: 455-460.
21. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31: 173-175.
22. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control. Diabetes Care 2005; 28: 600-606.
23. Peyrot M, Skovlund SE, Landgraf R. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin 2009; 25: 1985-1993.
24. Donnelly LA, Morris AD, Evans JM, DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007; 100: 345-350.
25. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-767.
26. Yki-Jarvinen H, Ryysy L, Kaupilla M, et al. Effect of obesity on the response to insulin therapy in non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 4037-4043.
27. Rašlová K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007; 27: 279-285.
28. Dornhorst A, Lüddeke HJ, Sreenan S, et al. PREDICTIVE Study Group. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008; 62: 659-665.
29. Hollander P, Cooper J, Bregnhoj J, Pederson CB. A 52-week multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008; 30: 1976-1987.
30. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24: 635-642.
31. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when added to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.
32. Barnett AH. Treating to goal: challenges of current management. Eur J Endo 2004; 151: T3-T7.
33. Concato J, Shaw N, Horwitz RI. Randomized, controlled trials, observational studies and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892.
34. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000; 342: 1907-1909.
35. Von Elm E, Altman DG, Egger M, et al. for the STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Bull WHO 2007; 85: 867-872.
36. Ligthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther 2007; 29: 1284-1292.